A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome

NCT07285005 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Venous Malformations
Lymphatic Malformations
Klippel-Trenaunay Syndrome
CLOVES Syndrome

Interventions

DRUG: KP-001
DRUG: Placebo

Sponsor

Kaken Pharmaceutical